Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028300 | 0.85 | NR1H3 (0.43) | NR1H3MEN1KMT2ACA12CA1 | |
| SCHEMBL10729758 | 0.79 | JUN (0.52) | NR1H3CASP1MEN1KMT2AHTT | |
| SCHEMBL17028351 | 0.79 | KMT2A (0.47) | NR1H3MEN1KMT2A | |
| SCHEMBL17028394 | 0.77 | RAB9A (0.46) | NR1H3MEN1KMT2AHTTCA12 | |
| SCHEMBL17028325 | 0.76 | TACR1 (0.43) | NR1H3CA9SCN2A | |
| SCHEMBL17028361 | 0.75 | DPP4 (0.45) | NR1H3MEN1KMT2A | |
| SCHEMBL22129224 | 0.73 | KMT2A (0.58) | NR1H3CHRM5MEN1KMT2ACA12 | |
| SCHEMBL11753893 | 0.72 | MEN1 (0.54) | NR1H3MEN1KMT2AGALR3HTR4 | |
| SCHEMBL17028322 | 0.72 | NR1H3 (0.42) | NR1H3PARK7MEN1KMT2A | |
| SCHEMBL18946253 | 0.72 | PARK7 (0.45) | NR1H3PARK7CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-01-19 | — | — | US | disclosed |
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-01-19 | — | — | US | disclosed |
| EP-3110817-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015125125-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015125125-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | CHRM2, RPS4Y1, CHRM4 | NR1H3 1839/4885PARK7 3895/4885CASP1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.